TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.